UNSPSC 51383315: Diclofenac sodium

This classification denotes a cyclooxygenase inhibitor with the molecular formula C14H10Cl2NO2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QTG126297Q, chemically known as 2-((2,6-dichlorophenyl)amino)benzeneacetic acid but more generally known as diclofenac sodium, which bears US NIH Compound Identifier 3033. European Medicines Agency schedules Diclofenac sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01674MIG.

Most nations, for tariff and trade purposes, schedule diclofenac sodium under HS 29224995 and SITC 51465. As of Q4 2014, DICLOFENAC SODIUM remains US FDA's Preferred Term for this commodity. Diclofenac sodium bears US NLM identifiers UMLS ID C0700583 and NCI Concept Code C47984. SMILES: C1CCC(C(C1)CC(=O)[O-])NC2C(CCCC2CL)CL.[NA+].

UNSPSC 51383315 Diclofenac sodium is a Commodity code that maps poorly to the state and local solicitations posted under it. The recent opportunities capture naloxone and drug deactivation systems procurement (Seminole County, Florida), a Texas Health and Human Services Commission RFI exploring direct-to-manufacturer prescription programs, and a Minnesota multistate cooperative purchasing alliance RFP for generic multi-source pharmaceuticals and OTC products — none of which center on diclofenac sodium specifically. State and local governments do purchase pharmaceuticals through cooperative and individual procurement channels, but the code's nominal product does not appear in the posted opportunities, suggesting either a tagging misalignment or minimal recent activity specifically for diclofenac sodium at the state and local level.

Activity under this code appears scattered across state health and human services departments, county health systems, and multistate purchasing cooperatives rather than concentrated in any single jurisdiction or buying pattern. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted an RFP on January 20, 2026, due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with awards effective July 1, 2026. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, due July 26, 2023, for naloxone and drug deactivation systems with quarterly deliveries. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to explore direct-to-manufacturer prescription fulfillment models. Geographic reach spans Florida, Texas, Minnesota, and Oregon within the recent window, though the mismatch between the code's stated product and actual procurement scope limits confidence in forecasting future activity under this specific Commodity code.